How have the Point of Care (PoC) and rapid testing markets evolved over the past two years? What are the key challenges, unmet needs and opportunities for companies working in POC & rapid testing today?
The global public’s top 5 concerning issues remain unchanged, with Covid-19 still top. But inflation now ranks 6th with almost one in four (23%) worldwide now saying it is a worry in their country.
Whilst the global COVID-19 pandemic continued throughout 2021, new oncology drug and indication approvals maintained momentum across the US, Europe and Japan. These included continued roll-out and label expansions of Immuno-Oncology (I-O) therapies, along with treatments approved in Japan ahead of other global regions.
The clinical management of cancer patients has undergone a remarkable evolution in the last 15 years, with the concept of personalised medicine now well-entrenched in the treatment paradigm.
Living with a chronic illness is difficult, especially for children and young people. NHS England used ethnography to understand how to improve the lives of this group.
How has the Point of Care (PoC) and rapid testing market evolved, and what does the future hold? What are the key challenges, unmet needs and opportunities for companies working in PoC & rapid testing today?
At Ipsos we firmly believe the future will be driven by consumers and patients who will take a pro-active role in their health. From use of e-commerce for prescription and health information, digital health solutions and virtual care for remote care and signals of increased investment in smart home tech for at home care.
